| News
Basel’s Lyfegen closes seed financing round
18.04.2019
Lyfegen, an IT company specializing in healthcare from Basel, has raised 750,000 Swiss francs in a seed financing round. The startup has developed a software solution to overcome technical hurdles in value-based healthcare.

The founding team of the Lyfegen HealthTech AG
Value-based healthcare puts the spotlight on the successful treatment of patients. This involves assessing the outcome of treatment as a whole, rather than focusing on the quantity of drugs prescribed or medical appointments. In Lyfevalue, Basel startup Lyfegen has developed a platform that enables life sciences companies, national and private healthcare payers and healthcare providers to execute value-based pricing contracts. Lyfegen has now successfully closed its seed financing round, led by Swiss private investors, raising a total of 750,000 francs, it was reported in a press release.
Founded in October 2018, Lyfegen HealthTech AG will use these funds to further build its platform and conduct new pilot projects with partners in Africa, the EU and the USA. Lyfegen will therefore offer a platform that allows healthcare providers to operationalize value-based healthcare strategies, while fostering accelerated and facilitated access to innovative treatments for patients. “Enabling the shift to sustainable healthcare is a huge challenge, giving us at Lyfegen great purpose,” said Girisha Fernando, Lyfegen’s CEO & Founder.
The founders – Michel Mohler, Nico Mros, Leon Rebolledo and James Gannon, in addition to Girisha Fernando – previously worked at companies including Roche, Novartis and UBS. Subsequently, they created their software solution for Lyfegen to enter a market set to grow to US$390.7 billion by 2024, according to the press release. Lyfegen is accompanied and supported on its way by BaselArea.swiss.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Space Pharmaceuticals establishes presence in Basel
Space Pharmaceuticals AG is strengthening the life sciences cluster in the Basel Area. At its research lab, the cheminformatics company...
Read MoreNextImmune to benefit from Venture Kick financing
The startup accelerator Venture Kick is supporting NextImmune with financing in the amount of 150,000 Swiss francs. The spin-off from...
Read MoreOECD impressed by the canton of Jura’s innovation system
The OECD has examined the innovation systems in place in rural areas of its member states, including the canton of...
Read Moreti&m opens branch in Basel
ti&m now has an office in Basel. With this action, the company specializing in digitization, security and innovation projects is...
Read MoreWhat can artificial intelligence do for health?
Algorithms help diagnose and treat diseases, discover new drugs and personalize prevention. Thus, the potential of artificial intelligence has been...
Read MoreEconomic promotion agency creates 55 new jobs in Jura
The economic promotion agency of the canton of Jura supported a total of 26 companies in founding, establishing a presence...
Read MoreInvestors top up capital of BioVersys
BioVersys has raised 24.2 million Swiss francs in a series C funding round. The Basel-based pharmaceutical company plans to use...
Read MoreSwiss made software label awarded to 1000th company
Swiss made software GmbH has now awarded its seal of quality to its 1,000th member firm. The “swiss made software”...
Read MoreEvokAI to acquire Advancience
EvokAI Creative Labs Inc. has agreed a deal to acquire Advancience. The diagnosis profiles enhanced by Artificial Intelligence (AI) developed...
Read MoreBeiGene opens European headquarters in Basel
BeiGene has opened its new European headquarters in Basel. The global biotech specializing in innovative cancer treatments intends to build...
Read More